GW 181771
Alternative Names: GI 181771; GSKI-181771X; GW-181771Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class Obesity therapies
- Mechanism of Action Cholecystokinin A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bulimia nervosa; Obesity
Most Recent Events
- 11 May 2017 Discontinued - Phase-II for Bulimia nervosa in USA (unspecified route)
- 26 Apr 2017 GlaxoSmithKline terminates a phase II trial in Bulimia nervosa in USA as the drug expired before the trial was completed (NCT00600743)
- 21 Apr 2005 Discontinued - Phase-II for Obesity in United Kingdom (unspecified route)